Battle Over Dementia Drug Swap Has Big Stakes For Drugmakers, Consumers

Executives at drug company Actavis knew they had to move fast to avoid a plunge in sales of their top-selling drug, Namenda, a treatment for Alzheimer’s disease which would lose patent protection in July.

When that happened, generic knockoffs would flood the market and doctors and pharmacists could switch patients to the lower-cost equivalents.